<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00110942</url>
  </required_header>
  <id_info>
    <org_study_id>20040166</org_study_id>
    <nct_id>NCT00110942</nct_id>
  </id_info>
  <brief_title>Treatment for Patients With Osteoarthritis (OA)</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Systemic AMG 108 in Subjects With Osteoarthritis (OA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the clinical benefit (change in Western Ontario and
      McMaster University Osteoarthritis Index [WOMAC] pain score) of AMG 108 (300 mg
      subcutaneously [SC] every 4 weeks) in subjects with OA.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2005</start_date>
  <completion_date type="Actual">November 2005</completion_date>
  <primary_completion_date type="Actual">June 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in WOMAC pain score</measure>
    <time_frame>Week 6</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in WOMAC pain score</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in WOMAC composite score and function and stiffness index scores</measure>
    <time_frame>Weeks 6 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Achieving 50% or more improvement from Day 1 in the WOMAC</measure>
    <time_frame>Weeks 6 and 12</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">160</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Minor sub-study AMG 108</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>N = 15</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Minor sub-study placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>N = 15</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Main sub-study AMG 108</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>N = 73</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Main sub-study placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>N = 73</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Systemic AMG 108</intervention_name>
    <description>300 mg SC AMG 108 Q4W for 3 doses</description>
    <arm_group_label>Main sub-study AMG 108</arm_group_label>
    <arm_group_label>Minor sub-study AMG 108</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>SC placebo injection Q4W for 3 doses</description>
    <arm_group_label>Main sub-study placebo</arm_group_label>
    <arm_group_label>Minor sub-study placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with knee OA as determined by American College of Rheumatology (ACR)
             criteria

          -  Pain defined by a level of greater than or equal to 30 mm on a 100 mm Visual Analogue
             Scale (VAS)

          -  If currently taking any over the counter nutritional supplements, must be on stable
             doses for greater than 2 months prior to screening

          -  If utilizing physical therapy, biomechanical devices or orthotic support, must have
             been using treatment or device for greater than or equal to 2 months prior to
             screening

          -  If currently or previously taking any non-prescribed supplement (e.g., glucosamine or
             chondroitin sulphate, shark cartilage, diacerein, soya extract, etc.) must be on
             stable doses for at least 2 months prior to screening

          -  If currently taking nonsteroidal anti-inflammatory drugs (NSAIDs), must be on stable
             doses for at least 2 months prior to screening

          -  Able to discontinue NSAIDs at least 5 half-lives (approximately 3 days) prior to Day 1

          -  Radiographic evidence of tibio-femoral compartment knee OA within 12 months of
             screening

          -  Signed written informed consent

        Exclusion Criteria:

          -  Malignancy within the previous 5 years, except for basal cell or in situ cancer

          -  Significant hematologic disease - Active infection or history of recurrent or chronic
             infections

          -  Known diagnosis of HIV, hepatitis B, or hepatitis C infection

          -  Uncontrolled diabetes or cardiovascular disease and hypertension

          -  Inflammatory arthropathy including secondary OA

          -  Isolated OA of the patellofemoral joint (bi or tri-compartmental involvement are not
             exclusions)

          -  End-stage (&quot;bone-on-bone&quot;) OA (Kellgren Lawrence score of 4)

          -  OA of the hip ipsilateral to the index knee - Total white cell count less than 2.0 x
             10^9/L and/or platelet count less than 100 x 10^9/L observed within 1 month preceding
             screening

          -  Prior intra-articular (IA) injection of anakinra or experimental interleukin-1 (IL-1)
             inhibitor therapy - Concurrent treatment with SC anakinra

          -  Concurrent or recent (less than or equal to 1 month) use of experimental therapy

          -  Prior IA corticosteroid injection within 1 month of study

          -  Prior viscosupplement therapy within 3 months of study

          -  Contraindication(s) to IA injections

          -  Subjects who are pregnant or breast-feeding, or plan to become pregnant during the
             study

          -  Subject is not using adequate contraception

          -  Known allergy to E coli-derived products

          -  Unable to understand informed consent

          -  Concerns regarding subject's compliance with the protocol procedures

          -  Subject will not be available for follow-up assessment

          -  Active substance abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <removed_countries>
    <country>Australia</country>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>June 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 16, 2005</study_first_submitted>
  <study_first_submitted_qc>May 16, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2005</study_first_posted>
  <last_update_submitted>June 20, 2008</last_update_submitted>
  <last_update_submitted_qc>June 20, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 23, 2008</last_update_posted>
  <responsible_party>
    <name_title>Global Development Leader</name_title>
    <organization>Amgen Inc.</organization>
  </responsible_party>
  <keyword>Intra-articular</keyword>
  <keyword>Osteoarthritis</keyword>
  <keyword>OA</keyword>
  <keyword>anakinra</keyword>
  <keyword>Amgen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

